Journals / Retina-Vitreus / 2021 / Cilt: 30 - Sayı: 4

The Effect of Epiretinal Membrane on Intravitreal Anti-Vegf Treatment in Diabetic Macula Edema

Pages
375–378
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: It was found that anti-VEGF (ranibizumab) treatment provided signifi cant improvement on CMT and BCVA (logMAR) values in cases with diabetic macular edema and epiretinal membrane

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: In the study we aimed to investigate effect of concomitant epiretinal membrane on results of anti-VEGF treatment in diabetic macular edema.
📊
Key Findings & Data:Patients received initial loading doses of three injections; followed by 0.5 mg/month ranibizumab injections as needed.
💡
Conclusion & Impact:Conclusion: It was found that anti-VEGF (ranibizumab) treatment provided signifi cant improvement on CMT and BCVA (logMAR) values in cases with diabetic macular edema and epiretinal membrane
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Purpose: In the study we aimed to investigate effect of concomitant epiretinal membrane on results of anti-VEGF treatment in diabetic macular edema. Materials and Methods: In the study we included patients with epiretinal membrane and diabetic macular edema who were followed in the retina unit. Patients received initial loading doses of three injections; followed by 0.5 mg/month ranibizumab injections as needed. In all patients, central macular thickness, optical coherence tomography fi ndings and best-corrected visual acuity were evaluated. RESULTS: The study included 31 eyes of 37 patients (4 patients received bilateral treatment). The mean age of the patients was 62.4±7.4 years. The patients received an average of 3.9 doses of ranibizumab injection. In the study, 12 (38%) of 31 eyes underwent cataract surgery. The mean central macular thickness (CMT) was 429.25±127.41μm at baseline and 324.42±69.74 at the end of treatment (p 0.05). Conclusion: It was found that anti-VEGF (ranibizumab) treatment provided signifi cant improvement on CMT and BCVA (logMAR) values in cases with diabetic macular edema and epiretinal membrane

🔖

Cite This Article

KAYIKCIOĞLU, Ö. R., YILMAZLAR, A. A., DOĞRUYA, S. (2021). The Effect of Epiretinal Membrane on Intravitreal Anti-Vegf Treatment in Diabetic Macula Edema. Retina-Vitreus, Cilt: 30 - Sayı: 4, 375–378. https://ajindex.com/articles/400352

References (16)

  1. Fraser-Bell S, Guzowski M, Rochtchina E, et al. Fiveyear cumulative incidence and progression of epiretinal membranes: the Blue Mountains Eye Study. Ophthalmology 2003; 110: 34-40
  2. Tsotridou E, Loukovitis E, Zapsalis K, et al. A Review of Last Decade Developments on Epiretinal Membrane Pathogenesis. Med Hypothesis Discov Innov Ophthalmol 2020; 9:91- 110
  3. Perente I, Erdogan G, Eriş E, et al. Secondary epiretinal membrane following rhegmatogenous retinal detachment. Photodiagnosis Photodyn Ther 2020; 31: 101833
  4. Loiudice P, Sartini F, Figus M, et al. Secondary epiretinal membrane after Ex-Press glaucoma fi ltration device implant. Graefes Arch Clin Exp Ophthalmol 2020
  5. Kang YK, Park HS, Park DH, et al. Incidence and treatment outcomes of secondary epiretinal membrane following intravitreal injection for diabetic macular edema. Sci Rep 2020; 10: 528
  6. You Q, Xu L, Jonas JB. Prevalence and associations of epiretinal membranes in adult Chinese: the Beijing eye study. Eye (Lond) 2008; 22: 874-9
  7. Ng CH, Cheung N, Wang JJ, et al. Prevalence and risk factors for epiretinal membranes in a multi-ethnic United States population. Ophthalmology 2011; 118: 694-9
  8. Ghazi-Nouri SM, Tranos PG, Rubin GS, et al. Visual function and quality of life following vitrectomy and epiretinal membrane peel surgery. Br J Ophthalmol 2006; 90: 559-62
  9. Dupas B, Tadayoni R, Gaudric A. [Epiretinal membranes]. J Fr Ophtalmol 2015; 38: 861-75
  10. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009; 54: 1-32
  11. Johnson MW. Etiology and treatment of macular edema. Am J Ophthalmol 2009; 147: 11-21.e1
  12. Virgili G, Parravano M, Evans JR, et al. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev 2018; 10: Cd007419
  13. Elman MJ, Ayala A, Bressler NM, et al. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. 242 Ophthalmology 2015; 122: 375-81
  14. Tsanou E, Ioachim E, Stefaniotou M, et al. Immunohistochemical study of angiogenesis and proliferative activity in epiretinal membranes. Int J Clin Pract 2005; 59: 1157-61
  15. Nam DH, Oh J, Roh JH, et al. Different expression of vascular endothelial growth factor and pigment epithelium derived factor between diabetic and non- diabetic epiretinal membranes. Ophthalmologica 2009; 223: 188-91
  16. Harada C, Mitamura